

DCVax(®) (Northwest Biotherapeutics, Inc., MD, USA) is a platform technology for delivering **dendritic cell vaccines** for a variety of **cancers**, including **glioblastoma multiforme** (GBM).

---

DCVax, a dendritic cell-based immunotherapy, is an active immunization platform being developed by Northwest Biotherapeutics for the potential treatment of multiple malignancies, including hormone-refractory metastatic prostate cancer, non-small-cell lung cancer, renal cancer and glioblastoma multiforme. The DCVax platform is tailored to a specific cancer type with either purified tumor-specific antigen or tumor cell extracts derived from patients at the time of resection. Phase I/II clinical trials of DCVax-Prostate have been completed, and phase III clinical trials have recently been initiated. DCVax-Lung recently received approval from the US FDA for phase I clinical trials <sup>1)</sup>.

see [DCVax-L](#).

<sup>1)</sup>

Knutson KL. Technology evaluation: DCVax, Northwest Biotherapeutics. Curr Opin Mol Ther. 2002 Aug;4(4):403-7. PubMed PMID: 12222879.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=dcvax>

Last update: **2025/05/13 02:04**

